X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (15) 15
index medicus (14) 14
animals (13) 13
mice (11) 11
oncology (11) 11
cell line, tumor (9) 9
crizotinib (7) 7
female (7) 7
cancer (6) 6
hemic and lymphatic diseases (6) 6
mutation (6) 6
protein kinase inhibitors - pharmacology (6) 6
analysis (5) 5
anaplastic lymphoma kinase (5) 5
lymphomas (5) 5
male (5) 5
protein-tyrosine kinases - genetics (5) 5
protein-tyrosine kinases - metabolism (5) 5
resistance (5) 5
transfection (5) 5
acquired-resistance (4) 4
alk (4) 4
lymphoma, large-cell, anaplastic - pathology (4) 4
pyrazoles - pharmacology (4) 4
pyridines - pharmacology (4) 4
receptor protein-tyrosine kinases - antagonists & inhibitors (4) 4
research article (4) 4
signal transduction (4) 4
agriculture, dairy & animal science (3) 3
cancer therapies (3) 3
care and treatment (3) 3
cell biology (3) 3
cell lung-cancer (3) 3
chronic myeloid-leukemia (3) 3
cucurbita pepo (3) 3
disease (3) 3
drug resistance, neoplasm (3) 3
drug synergism (3) 3
environment (3) 3
health aspects (3) 3
hematology (3) 3
horticulture (3) 3
inhibitors (3) 3
kinases (3) 3
lactation (3) 3
leukemia, myelogenous, chronic, bcr-abl positive - drug therapy (3) 3
lung-cancer (3) 3
lymphoma, large-cell, anaplastic - drug therapy (3) 3
lymphoma, large-cell, anaplastic - genetics (3) 3
mechanisms (3) 3
mice, nude (3) 3
microscopy, confocal (3) 3
npm-alk (3) 3
prevention (3) 3
protein-tyrosine kinases - antagonists & inhibitors (3) 3
psychiatry (3) 3
sensitivity (3) 3
tumors (3) 3
tyrosine (3) 3
tyrosine kinase (3) 3
veterinary sciences (3) 3
activating mutations (2) 2
activation (2) 2
alcl (2) 2
aniline compounds - administration & dosage (2) 2
aniline compounds - metabolism (2) 2
aniline compounds - therapeutic use (2) 2
antineoplastic agents - pharmacology (2) 2
antineoplastic agents - therapeutic use (2) 2
antineoplastic combined chemotherapy protocols - therapeutic use (2) 2
apoptosis (2) 2
apoptosis - drug effects (2) 2
argentina (2) 2
article (2) 2
atp binding cassette transporter, sub-family b - drug effects (2) 2
carcinoma (2) 2
cardiac patients (2) 2
cell proliferation (2) 2
cell proliferation - drug effects (2) 2
cells (2) 2
chemotherapy (2) 2
chlorophyll (2) 2
colorectal neoplasms - genetics (2) 2
colorectal neoplasms - metabolism (2) 2
cytotoxicity (2) 2
down-regulation (2) 2
drug administration schedule (2) 2
drug resistance (2) 2
drug resistance, neoplasm - genetics (2) 2
drug transporters (2) 2
ecosystem services (2) 2
elderly-patients (2) 2
expression (2) 2
fusion (2) 2
gene (2) 2
gene expression (2) 2
gene expression regulation, neoplastic (2) 2
genetic aspects (2) 2
goat (2) 2
identification (2) 2
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Translational Lung Cancer Research, ISSN 2218-6751, 2014, Volume 3, Issue 6, pp. 376 - 378
Ceritinib, also known as LDK-378 or Zykadia (Novartis), is a second generation inhibitor able to specifically target the anaplastic lymphoma kinase (ALK). In... 
Crizotinib | Drug resistance | Non-small cell lung cancer (NSCLC) | Anaplastic lymphoma kinase (ALK) | crizotinib | drug resistance | non-small cell lung cancer (NSCLC)
Journal Article
Journal of the National Cancer Institute, ISSN 0027-8874, 2014, Volume 106, Issue 2, pp. djt378 - djt378
Journal Article
PLoS ONE, ISSN 1932-6203, 12/2012, Volume 7, Issue 12, pp. e51449 - e51449
Activation of Wnt signalling due to inability to degrade beta-catenin is found in >85% of colorectal cancers. Approximately half of colon cancers express a... 
COLON-CANCER | CARCINOMA-CELLS | IN-VITRO | K-RAS | THYROID CARCINOMAS | MULTIDISCIPLINARY SCIENCES | PYRVINIUM PAMOATE | PANCREATIC TUMOR-GROWTH | BETA-CATENIN | FARNESYLTHIOSALICYLIC ACID | PROMOTES APOPTOSIS | Proto-Oncogene Proteins p21(ras) | Colorectal Neoplasms - genetics | Farnesol - pharmacology | Humans | ras Proteins - metabolism | Wnt Proteins - metabolism | Antineoplastic Combined Chemotherapy Protocols - pharmacology | Salicylates - chemistry | Salicylates - pharmacology | Colorectal Neoplasms - drug therapy | Gene Expression Regulation, Neoplastic - drug effects | Colorectal Neoplasms - metabolism | Farnesol - chemistry | Perylene - analogs & derivatives | Proto-Oncogene Proteins - metabolism | Proto-Oncogene Proteins - antagonists & inhibitors | Perylene - chemistry | Pyrvinium Compounds - chemistry | ras Proteins - antagonists & inhibitors | Perylene - pharmacology | Drug Synergism | Animals | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Cell Line, Tumor | Farnesol - analogs & derivatives | Mice | Wnt Proteins - antagonists & inhibitors | Pyrvinium Compounds - pharmacology | Prevention | Gene mutations | Cell death | Analysis | Genes | Cancer cells | Colorectal cancer | Health aspects | Cancer | Health sciences | Biotechnology | Wnt protein | Transcription | Gene regulation | Colorectal carcinoma | Genomes | Myc protein | Kinases | Cancer therapies | Synergism | K-Ras protein | Proteins | Synergistic effects | β-catenin | Cell growth | Colon cancer | CD44 antigen | Colon | Inhibition | RNA-mediated interference | Abnormalities | Cyclin-dependent kinases | Survivin | Gene expression | Signaling | Inhibitors | Mutation | Apoptosis | Index Medicus
Journal Article
Journal Article
American Journal of Hematology, ISSN 0361-8609, 11/2012, Volume 87, Issue 11, pp. E125 - E128
BCR/ABL (Breakpoint Cluster Region protein/Abelson tyrosine-protein kinase 1) kinase domain (KD) mutations represent the most frequently described mechanism of... 
CELLS | IN-VITRO | IMATINIB | ALPHA-1-ACID GLYCOPROTEIN | RESISTANCE | MECHANISMS | MUTATIONS | HEMATOLOGY | BCR-ABL INHIBITOR | CHRONIC MYELOID-LEUKEMIA | T315I MUTANT | Humans | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - drug therapy | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - genetics | Antineoplastic Agents - therapeutic use | Structure-Activity Relationship | Precursor Cell Lymphoblastic Leukemia-Lymphoma - drug therapy | Sequence Analysis, Protein | Protein Kinase Inhibitors - chemistry | Protein-Tyrosine Kinases - genetics | Transfection | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - pathology | Protein-Tyrosine Kinases - chemistry | Antineoplastic Agents - pharmacology | Cell Culture Techniques | Tumor Cells, Cultured | Precursor Cell Lymphoblastic Leukemia-Lymphoma - pathology | Fusion Proteins, bcr-abl - chemistry | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - enzymology | Mutagenesis, Site-Directed | Antineoplastic Agents - chemistry | Precursor Cell Lymphoblastic Leukemia-Lymphoma - genetics | Drug Resistance, Neoplasm - genetics | Fusion Proteins, bcr-abl - genetics | Animals | Protein Kinase Inhibitors - therapeutic use | Fusion Proteins, bcr-abl - antagonists & inhibitors | Precursor Cell Lymphoblastic Leukemia-Lymphoma - enzymology | Mice | Protein Kinase Inhibitors - pharmacology | Mutation | Protein-Tyrosine Kinases - antagonists & inhibitors | Tyrosine | Index Medicus
Journal Article
Cancer Research, ISSN 0008-5472, 07/2018, Volume 78, Issue 13 Supplement, pp. 902 - 902
Journal Article
Journal of Clinical Investigation, ISSN 0021-9738, 09/2015, Volume 125, Issue 9, pp. 3505 - 3518
The regulatory microRNA miR-150 is involved in the development of hemopathies and is downregulated in T-lymphomas, such as anaplastic large-cell lymphoma... 
ANAPLASTIC LYMPHOMA KINASE | MEDICINE, RESEARCH & EXPERIMENTAL | DNA METHYLTRANSFERASE 1 | LUNG-CANCER | TUMOR-SUPPRESSOR MICRORNAS | NPM-ALK | TYROSINE KINASE | THERAPEUTIC TARGET | DOWN-REGULATION | C-MYB | ACTIVATING MUTATIONS | Protein-Tyrosine Kinases - metabolism | Humans | Gene Expression Regulation, Neoplastic | Drug Resistance, Neoplasm | Male | DNA (Cytosine-5-)-Methyltransferases - metabolism | Protein-Tyrosine Kinases - genetics | Female | Lymphoma, Large-Cell, Anaplastic - metabolism | STAT3 Transcription Factor - genetics | STAT3 Transcription Factor - metabolism | Lymphoma, Large-Cell, Anaplastic - genetics | Pyrazoles - pharmacology | DNA (Cytosine-5-)-Methyltransferase 1 | Gene Silencing | Mice, Transgenic | MicroRNAs - biosynthesis | DNA (Cytosine-5-)-Methyltransferases - genetics | Animals | RNA, Neoplasm - biosynthesis | Lymphoma, Large-Cell, Anaplastic - drug therapy | Cell Line, Tumor | RNA, Neoplasm - genetics | Lymphoma, Large-Cell, Anaplastic - pathology | Mice | MicroRNAs - genetics | Pyridines - pharmacology | Crizotinib | Usage | MicroRNA | Genetic aspects | Research | Non-Hodgkin's lymphomas | Health aspects | Risk factors | Disease | Kinases | Gene expression | Cancer therapies | Chemotherapy | Disadvantages | Medical prognosis | MicroRNAs | DNA methylation | Epigenetics | Lymphomas | Mutation | Deoxyribonucleic acid--DNA | Tumors | Cancer | Index Medicus | Abridged Index Medicus | Life Sciences
Journal Article
Journal of Hematology and Oncology, ISSN 1756-8722, 07/2015, Volume 8, Issue 1, pp. 81 - 81
Background: Bosutinib is a recently approved ABL inhibitor. In spite of the well-documented effectiveness of BCR-ABL inhibitors in treating chronic myeloid... 
Resistance | CML | TKI | Drug transporters | CHRONIC MYELOGENOUS LEUKEMIA | OCT-1 ACTIVITY | BCR-ABL | CELL-LINES | CHRONIC MYELOID-LEUKEMIA | P-GLYCOPROTEIN | ABL INHIBITOR | ONCOLOGY | HEMATOLOGY | IMATINIB MESYLATE | Animal experimentation | Tyrosine | Care and treatment | Medical equipment and supplies industry | Medical test kit industry | Cancer | Index Medicus
Journal Article
Cancers, ISSN 2072-6694, 12/2018, Volume 10, Issue 12, p. 509
Targeted therapy is an effective, rational, and safe approach to solid and hematological tumors treatment. Unfortunately, a significant fraction of patients... 
Inhibitors | Personalized medicine | Targeted therapy | Oncogene | Cancer | ALK | inhibitors | targeted therapy | ACQUIRED-RESISTANCE | SENSITIVITY | FOLLOW-UP | MECHANISMS | oncogene | personalized medicine | CHRONIC MYELOID-LEUKEMIA | CELL LUNG-CANCER | ONCOLOGY | DRUG-ADDICTION | CRIZOTINIB | cancer
Journal Article
Cancer Research, ISSN 0008-5472, 08/2015, Volume 75, Issue 15 Supplement, pp. 3583 - 3583
Journal Article
Experimental and Clinical Endocrinology & Diabetes, ISSN 0947-7349, 11/2018
Abstract Background Enhanced platelet reactivity represents one of the major determinants of cardiovascular risk among diabetic patients. The aim of the... 
Article
Journal Article
Journal Article
Cancer Research, ISSN 0008-5472, 12/2018, Volume 78, Issue 24, pp. 6866 - 6880
Targeted therapy changed the standard of care in ALK-dependent tumors. However, resistance remains a major challenge. Lorlatinib is a third-generation ALK... 
ACTIVATION | GROWTH-FACTOR-RECEPTOR | ONCOLOGY | PATHWAY | TYROSINE KINASE | ACQUIRED-RESISTANCE | LUNG ADENOCARCINOMA | CRIZOTINIB | SENSITIVITY | TUMOR-CELLS | ALK/ROS1 INHIBITOR
Journal Article